Roivant Sciences Ltd. Common Shares - ROIV STOCK NEWS

Genevant Sciences and Arbutus Biopharma have filed a lawsuit against Moderna for patent infringement related to key patents in nucleic acid delivery technology used in the manufacture of their COVID-19 vaccine, mRNA-1273. The patents involved include U.S. Patent Nos. 8,058,069, 8,492,359, and others. Importantly, Genevant and Arbutus are not seeking to halt the sale or distribution of mRNA-1273. The lawsuit follows a recent legal victory for Genevant and Arbutus, where a court upheld the patentability of their technologies.

Genevant emphasizes the significance of lipid nanoparticle technology in mRNA delivery.

Roivant Sciences has launched Hemavant, a subsidiary that secured a licensing agreement with Eisai Co., Ltd. for RVT-2001, targeting anemia in myelodysplastic syndromes. Dermavant is preparing for the anticipated FDA decision on tapinarof for psoriasis, with favorable Phase 3 trial results in atopic dermatitis. Genevant's patent portfolio was upheld against Moderna, and Immunovant aligned with the FDA for a pivotal trial in myasthenia gravis. As of December 31, 2021, Roivant reported $2.2 billion in cash, with a net loss of $306.1 million for the quarter.

Roivant Sciences (NASDAQ: ROIV) will host a live conference call and webcast on February 14, 2022, at 8:00 a.m. ET to discuss its Q3 2021 financial results and provide a corporate update. The call can be accessed at +1-844-224-1923 for domestic and +1-214-989-7105 for international calls. Roivant will also present at three major healthcare conferences this February and March, including the SVB Leerink Global Healthcare Conference and Cowen Healthcare Conference.

Roivant Sciences (Nasdaq: ROIV) announced CEO Matt Gline will present at two conferences: the B. Riley Securities Virtual Oncology Conference on January 27, 2022, at 12:30 p.m. ET, and the SVB Leerink Global Healthcare Conference on February 17, 2022, at 1:00 p.m. ET. Live webcasts will be available on the Roivant investor website, with archived recordings accessible for 30 days. Roivant aims to enhance healthcare delivery and develop transformative medicines through its innovative platform.

TandemAI has appointed Albert Pan, Ph.D., as Chief Technology Officer and Lanny Sun as Chairman of the Board of Directors. Dr. Pan brings over 20 years of experience in molecular simulation and drug discovery, previously at D.E. Shaw Research. Sun is a seasoned executive with a strong biotechnology background, co-founding Silicon Therapeutics, which was acquired by Roivant Sciences in 2021. TandemAI recently completed a $25 million funding round to enhance its recruitment and expand drug discovery operations utilizing AI-based tools.

Roivant Sciences (Nasdaq: ROIV) announced a licensing agreement with Eisai Co., Ltd. for global rights to RVT-2001, aimed at treating transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (MDS). RVT-2001, an orally available small molecule, has been tested in over 80 human subjects. Roivant will expand its clinical trial for RVT-2001 this year. Details will be discussed during a presentation at the J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. ET.

Full-Life Technologies Co., Ltd. announces key executive appointments: Ravi Chari, Ph.D., as Chief Scientific Officer; Julie Wu as Chief Financial Officer; Philippe van Put as General Manager for Europe; and Lanny Sun as Chairman of the Board. These appointments follow a significant $10 million seed financing aimed at enhancing the company's nuclear medicine pipeline and manufacturing capabilities. Notably, Lanny Sun, previously CEO of Silicon Therapeutics, led its $2 billion acquisition by Roivant Sciences (NASDAQ:ROIV) in February 2021.

Roivant began trading on Nasdaq under the ticker ROIV and reported a cash balance of $2.5 billion. Dermavant presented positive results from its Phase 3 PSOARING 3 study of tapinarof for plaque psoriasis, highlighting that 58% of patients achieved a PGA score of 0 or 1 after long-term treatment. Aruvant shared encouraging data from its Phase 1/2 trial of ARU-1801 in sickle cell disease, with zero vaso-occlusive events observed for up to 18 months. Roivant's net loss was $225.6 million for the quarter, significantly up from $53.5 million year-over-year.

Roivant Sciences (Nasdaq: ROIV) has announced a quarterly investor call on November 15, 2021, at 8:00 a.m. ET to report its second quarter financial results. The company will also participate in the Jefferies London Healthcare Conference on November 17 and the Evercore ISI HealthCONx Conference on November 30. The call will be accessible via phone or webcast, with recordings available post-event. Roivant aims to enhance healthcare delivery by developing transformative medicines and technologies.